Identification of TRIM59 as a Key Biomarker for Ferroptosis Resistance and Immunotherapy Response in Bladder Cancer via Multi-Omics Integration and Machine Learning
Our integrative approach highlights the potential of genomic and immune microenvironment data in developing personalized risk models for BCa, offering insights into individualized treatment strategies. Importantly, <i>TRIM59</i> is involved in ferroptosis resistance in BCa. These findings have potential implications for identifying diagnostic biomarkers and therapeutic targets for BCa treatment.
Authors
- Hui Li (ORCID: https://orcid.org/0000-0002-3526-6664)
- Xianglian Zhang
- Xingfen Wang
- Ping Wang (ORCID: https://orcid.org/0000-0002-3492-7432)
- Pengyu Zhang (ORCID: https://orcid.org/0000-0002-1603-637X)
- Yanchun Qu (ORCID: https://orcid.org/0009-0009-0859-6607)
- Jianyuan Lei
Institutions
- Shanxi Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shaanxi Provincial People's Hospital (CN)
- Second Hospital of Tianjin Medical University (CN)
- Shanxi Provincial People’s Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-09-29
- DOI
- https://doi.org/10.31083/fbl44395
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tianjin Medical University